Daratumumab Combo Significantly Improved PFS for Relapsed Myeloma

Adding daratumumab to lenalidomide and dexamethasone significantly improved progression-free survival in patients with relapsed or refractory multiple myeloma.

Source: CancerNetwork - October 5, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news